Random C-peptide in the classification of diabetes

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 60, Issue 8, 2000, Pages 687-693

  Berger, B ^a   Stenstrom G ^b   Sundkvist, G ^c  

^a Departments of Medicine KSS Skövde   (Sweden)

^b Kungsbacka Hospital   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cut off values; Diabetes; Diagnosis; Fasting C peptide; Glucagon test; ROC curves; Type 1 diabetes; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLUCAGON;

ARTICLE; CONCENTRATION RESPONSE; CORRELATION FUNCTION; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; HORMONAL REGULATION; HUMAN; MEASUREMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

ADOLESCENT; ADULT; AGED; C-PEPTIDE; CHILD; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FASTING; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 0034507499     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510050216411     Document Type: Article

References (36)

1. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus: Provisional report of a WHO consultation
2. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus
3. Natural history of beta-cell dysfunction in NIDDM
4. Problems related to definition and epidemiology of type 2 (non-insulin-dependent) diabetes mellitus: Studies throughout the world
5. Classification of diabetes on the basis of etiologies versus degree of insulin deficiency
6. Diagnosing diabetes mellitus - Do we need new criteria?
7. Assays for insulin, proinsulin(s), and C-peptide
8. C-peptide
9. C-peptide uptake and excretion by the liver in man
10. Fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes
11. Plasma and urinary C-peptide in the classification of adult diabetics
12. Relationships between diabetes duration, metabolic control and β-cell function in representative population of type 2 diabetic patients in Sweden
13. Insulin therapy in relation to circulating C-peptide levels
14. Basal C-peptide in the discrimination of type I from type II diabetes
15. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus
16. Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin requiring based on clinical and biochemical variables
17. Standard breakfast test: An alternative to glucagon testing for C-peptide reserve
18. C-peptide and proinsulin after oral glucose
19. β-cell function in relation to islet cell antibodies during the first 3 years after clinical diagnosis of diabetes in type II diabetic patients
20. Difficulties in classifying diabetes at presentation in young adults
21. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus
22. Correlation between fasting serum C-peptide and B cell insulin secretory capacity in diabetes mellitus
23. The prevalence of diabetes in a Swedish population of 280 411 inhabitants: A report from the Skaraborg Diabetes Registry (SDR)
24. Incidence, prevalence, and mortality of diabetes in a large population
25. Practical aspects in performing the glucagon test in the measurement of C-peptide secretion in diabetic patients
26. The effect of various blood glucose levels on post-glucagon C-peptide secretion in type 2 (non insulin-dependent) diabetes
27. Användningen av ROC-kurvor för mätning och jämförelse av den diagnostiska förmågan hos test. Anvisningar för icke parametral statistisk granskning
28. The use of Relative Operating Characteristic (ROC) curves in test performance evaluation
29. The meaning and use of the area under a receiver operating characteristic (ROC) curve
30. The classification of diabetes by clinical and C-peptide criteria
31. B-cell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatment
32. Plasma C-peptide levels identify insulin-treated diabetic patients suitable for oral hypoglycaemic therapy
33. C-peptide determination in the choice of treatment in diabetes mellitus
34. Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type-2 diabetes mellitus
35. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus